	A. Un-Audited Financial Re	SUITS(Provisiona	ii) for the Quarter &	Nine Months ended 3	31st December 2012		(Rs. in Lecs)
	Particulars						(Ita: III Eaca)
			Unaudited		Unaudited Nine Months Ended		
Sr. No.			Quarter ended				Year ended
		3 months ended	Corresponding 3 months ended	Corresponding 3months ended in previous year	Year to Date Figures for the Current Period ended	Year to Date Figures for the Previous Period Ended	Current accounting year ended
		31.12.12	30.09.12	31.12.11	31.12.12	31.12.11	31.03.12
1	Sales/Income from operation(Net of Excise duty)	3548.74	2010.66	3776.57	7935.32	11164.43	15318,19
2	Other Operating Income	0.00	27.89		77.65		
3	Total Net Income from Operation	3548.74	2038.55	3780.78	8012.97	11176.63	
4	Expenditure						
	(a) Increase / decrease in stock in trade & work in					,	
	progress	(350.21)	380.44	195.47	697.73	(389.51)	(1576.15)
	(b) Consumption of raw materials	2981.79		2405.24	5392.74	7663.36	12444.85
	(c) Employees Cost	250.43		180.42	684.91	500.65	
	(d) Depreciation	97.78			293.35		
	(e) Other expenditure	550.40			1473.85		
	(f) Total	3530,19			8542.58	10139,17	
	Profit(+)/Loss(-) from operations before Other	***************************************					
	income,Finance cost and Exceptional Items(3-4)	18.55	(181.38)	294.94	(529.61)	1037.46	1095.25
	Other income	0.12	0.99	0.00	2.10	0.00	34.97
	Profit (+) / Loss (-) from ordinary activities before Finance						
	Cost & Exceptional Items(5+6)	18.67	(180.39)	294.94	(527.51)	1037.46	1130.22
	Finance Cost	268.67	243.48	269.94	749.04	712.48	1016.43
	Profit(+)/Loss(-) from ordinary activities after Finance cost						
	& Exceptional Items(7-8)	(250.00)	(423.87)	25.00	(1276.55)	325.00	113.79
	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
11	Profit(+)/Loss(-) before Tax (9-10)	(250,00)	(423.87)	25.00	(1276.55)	325.00	113,79
12	Tax Expenses(incl Deferred Tax)	0.00	0.00	4.00	0.00	69.00	50.42
13	Net Profit(+)/Loss(-) after Tax (11-12)	(250.00)	(423.87)	21.00	(1276.55)	256.00	63.37
14	Extraordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
15	Net Profit(+)/Loss(-) for the period(13-14)	(250.00)	(423.87)	21.00	(1276.55)	256.00	
16	Paid up Equity Share Capital (face value Rs.10/-each)	1317.82	1317.82	1317.82	1317.82	1317.82	1317.82
12	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year.	0.00	0.00	0.00	0.00	0.00	2488.35
	Earning per share (EPS)  (a) Basic and diluted EPS before extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	(1.90)	(3.22)	0.15	(9.69)	1.94	0.48
	(b) Basic and diluted EPS after extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	(1.90)	(3.22)	0.15	(9.69)	1.94	0.48
14	Non Promoters Shareholding	7548453	7548453	7602093	7548453	7602093	7518093
	- Number of shares - Percentage of shareholding	/546453 57.28		57.69	57.28	57.69	
15	Promoters and Promoter group Shareholding	91.20	31.20	51,05	07.20	01.00	97.00
	a) Pledged/ Encumbered						
	Number of Shares	1441095	1441095	1441095	1441095	1441095	1441095
	Percentage of Shares (as a % of the total	144,1093	1771085	1471030	ישעו דדו	111000	1117000
	shareholding of promoter & promoter group	25.60	25.60	25.84	25.60	25.84	25,46
	Percentage of Shares (as a % of the total	20.00	20.00		20.00		
	share capital of the company)	10.94	10.94	10.94	10,94	10.94	10.94
	b) Non-encumbered	10.04	10.54	10.04		,,,,,,	
	Number of Shares	4188700	4188700	4135060	4188700	4135060	4219060
	Percentage of Shares (as a % of the total	4100700	7100700	7,00000	4100700	710000	72.10000
	shareholding of promoter & promoter group)	74.40	74.40	74,16	74.40	74.16	74.54
	Percentage of Shares (as a % of the total	, 4,40	7 *****				
	share capital of the company)	31.78	31.78	31.37	31.78	31.37	32.01

## Notes:

- The above results have been reviewed by the Audit Committee and thereafter, were taken on record by the Board of Directors of the Company at their meeting held on 12th February 2013
- 2 During the Quarter & Nine Months ended 31st Dec 2012, 0 Investor complaint were received all of which have been attended by the company. No complaints were pending at the beginning or at the end of the quarter.
- 3 Previous year figure are regrouped wherever necessary.

Place: Mumbai Date: 12.02.2013 On behalf of Board of Directors For Mangalan Drugs & Organics Ltd

Director (Shri Govardhan M.Dhoot)

For MILWANI ASSOCIATES
Charter of the countaints

Marnbershir .0. 36099

Kernbershir .0. 36099

F.R. W. 106405W

## B. Segment Performance - Revenue and Results

Sr. No.	l Particulare I		Unaudited		Unaudited Nine Months Ended		(Rs in Lacs) Audited
			Quarter End	ed			
		Current Quarter ended 31,12.12	Correspondi ng 3 months ended 30.09.12		Year to Date Figures for Current Period Ended 31,12,12	Year to Date Figures for the Previous Period Ended 31.12.11	Year to date figures for the current year ended 31,03,12
_1_	Segment Revenue						***************************************
a)	Bulk Drugs	3548.74	2010.66	3776,57	7935.32	11164.43	15318.19
	Total Revenue	3548.74	2010.66	3776.57	7935.32	11164.43	15318.19
2	Segment Results				· · · · · · · · · · · · · · · · · · ·	<u> </u>	
a)	Bulk Drugs	414.41	35.90	556.02	330.14	1834.54	2215.09
	Total Segement Results before interest and tax	414.41	35.90	556.02	330.14	1834.54	2215.09
	Less : i) Interest**	(268.67)	(243.48)	(269.94)	(749,04)	(712.46)	(1016.43)
	(ii) Other Un-allocable Expenditure	(395.74)	(216.29)	(261.08)	(857.65)	(797.08)	(1084.87)
	Total Profit/(Loss) Before Tax	(250.00)	(423.87)	25.00	(1276.55)	325.00	113.79

## Note:

Certain assets of the company are used by different segments for different portion of the accounting period. Hence the value of the assets cannot be allocated to the segments.

Current year and Previous years figures are regrouped/rearranged wherever necessary

On behalf of Board of Directors

For Mangalam Drugs & Organics Ltd.

Director

FR.N.:106405W 31-33. Dr. M. B. Velkar St. Mumbar-400 (992)

Shri. Govardhan M.Dhoot

Place: Mumbai

Date: 12th,February 2013

For MILWANI ASSOCIATES
Chartered Accountants

(CARakesh K. Milwani) Proprietor Membership No.: 36099 F.R.N.:106405W CA-Rakesh K. Milwani
B.Com., L.L.B., FCA.

18, Bagaria House, 1st Floor, 31/33, Dr. M.B.Velkar Lane, Mumbai - 400 002. Tel.: 22036132 / 9821162679 E-mail: rakesh\_milwani@hotmail.com

То

The Secretary

Stock Exchange, Mumbai

Phiroze Jeejeebhoy Towers,

Dalal Street,

Mumbai - 400 001.

To.

National Stock Exchange of India Limited

"Exchange Plaza",

Bandra - Kurla Complex,

Bandra (E),

Mumbai – 400 051.

## LIMITED REVIEW REPORT

We have reviewed the accompanying statement of unaudited financial results of Mangalam Drugs & Organics Ltd. having its registered office at 292, Princess Street, Second Floor, Near Flyover, Mumbai – 400 002; for the quarter and nine months ended 31st December, 2012 except for the disclosures regarding 'Public share holding' and 'Promoter and Promoter group share holding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express such an opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place

: Mumbai

Date

: 12th February, 2013.

PROPRIETOK: MILE II ASSOCIATES

Membership No.36099

MILWANI)

Firm Registration No.:106405W